Sucroferric Oxyhydroxide Helps More Hyperphosphatemia Pts Reach Target
Patients also needed fewer phosphate binder pills over time.
CHICAGO—In clinical practice, 12 months of sucroferric oxyhydroxide treatment can help hyperphosphatemia patients reduce their serum phosphorus levels to 5.5 mg/dL and below, according to study findings presented at the American Society of Nephrology's 2016 Kidney meeting.
“Sucroferric oxyhydroxide offers a new and effective treatment for control of serum phosphorus with reduced pill burden in chronic kidney disease patients on dialysis,” lead investigator Linda H. Ficociello, PhD, of Fresenius Medical Care North America (FMCNA), told Renal & Urology News.
She and her FMCNA colleagues conducted a retrospective study that included 306 patients (average age 54.2 years; 55.2% white, and 39.9% black) from Fresenius Kidney Care who had switched to sucroferric oxyhydroxide, an iron-based binder, from another phosphate binder, including sevelamer (60.1%), calcium acetate (32%) and lanthanum carbonate (7.9%), during routine care. In total, 82.5% still had hyperphosphatemia with an average serum phosphorus level of 7.0 mg/dL.
After 1 year of therapy, Dr Ficociello's group found that 31% to 42.1% of patients experienced normalization of phosphorus levels compared with 17.5% at baseline. The proportion of patients with elevated serum phosphorus of 5.6 to 8.5 mg/dL decreased from 64.7% at baseline to 50.6% at 1 year. Over the same period, patients needed fewer phosphate binder pills, declining from 8.3 at baseline to 4.1–4.3, on average.
The study was funded by FMCNA, the makers of sucroferric oxyhydroxide (Velphoro).
- Ficociello LH, Parameswaran V, Van Zandt CR, et al. Serum Phosphorus and Pill Number per Day in Hyperphosphatemic Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide for 12 Months. Presented at: Kidney Week 2016. November 15-20, 2016. Chicago. Abstract FR-PO420.